C-LEPPAmprion
seed amplification assay, alpha-synuclein, CSF diagnostics
diagnostics
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-LEPP
C-LEPPC-LEPPseed amplification assay, alpha-synuclein, CSF diagnostics
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Amprion seed amplification assay, alpha-synuclein, CSF diagnostics
Amprion develops and offers SAAmplify-ɑSYN, a clinically available validated test for detecting pathological alpha-synuclein in CSF. The site describes the test as providing biological clarity for diseases including Parkinson's, Lewy body dementia, and atypical Alzheimer's. Amprion positions the assay for clinicians, patients, researchers, and biopharma partners.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Amprion — Near-term readout · Upper middle. Derived deterministically from 2 extracted project(s). Most-advanced status: approved. Band: near_readout. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic